ClinicalTrials.gg
CompletedNCT04545944Updated Mar 17, 2023Results posted

Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Participants

A Phase 1 interventional study of Vonoprazan and Midazolam in Healthy Volunteers, sponsored by Phathom Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-17.

Sponsored by Phathom Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Study summary

To determine the time-dependent inhibition potential of repeated doses of oral vonoprazan on the pharmacokinetics (PK) of a single oral dose of midazolam, a sensitive cytochrome P450 3A4 (CYP3A4) substrate, in healthy participants.

Read the detailed description

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

02

Conditions studied

  • Healthy Volunteers

Keywords

  • vonoprazan
  • midazolam
03

In context

Lead sponsor

Phathom Pharmaceuticals, Inc. is the lead sponsor of 15 studies on the registry; 2 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 11 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant is male or female 18 to 45 years of age, inclusive, at Screening.
  2. The participant has a (BMI) 18 to 30 kg/m2, inclusive, and body weight >50 kg at Screening.
  3. The participant is considered by the investigator to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead results, and physical examination findings at Screening.
  4. Female participants of who may be sexually active with a non-sterilized male partner must use an acceptable method of (ie, diaphragm with spermicide, intrauterine device, condom with foam or vaginal spermicide, oral contraceptives, or abstinence) from the signing of until 4 weeks after the last dose of study drug or be surgically sterile (ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or (defined as amenorrhea for 12 consecutive months and documented plasma follicle-stimulating hormone [FSH] level >40 IU/mL).
  5. Female participants must have a negative pregnancy test at Screening and Check-in.
  6. The participant agrees to comply with all protocol requirements.
  7. The participant is able to provide written informed consent.

Exclusion criteria

Exclusion Criteria:

  1. The participant has a history of any neurological, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urological, hematological, or endocrine disease or other abnormality that may affect the ability of the subject to participate in the study.
  2. The participant has a positive test result for coronavirus disease 2019 (COVID-19), surface antigen, virus antibody, or type 1 or 2 antibodies at Screening.
  3. The participant has (ALT) or aspartate aminotransferase (AST) >2 × the (ULN) or total >1.5 × ULN (with the exception of Gilbert's syndrome) at Screening or Check-in.
  4. The participant has serum creatinine >1.2 mg/dL or blood urea nitrogen >20 mg/dL at Screening or Check-in.
  5. The participant has any acute laboratory abnormality at Screening that precludes participation in the study, in the opinion of the investigator.
  6. The participant has a current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome and asymptomatic gallstones).
  7. The subject has used any prescription (excluding hormonal ) or over-the-counter medications (including inducers) except paracetamol (up to 2 g per day), including herbal or nutritional supplements, within 14 days (or 5 half-lives) before the first dose of study drug or throughout the study.
  8. The subject has consumed grapefruit or grapefruit juice, Seville orange or Seville orange-containing products (eg, marmalade), or food products that may be CYP3A4 inhibitors (eg, vegetables from the mustard green family [kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard] and charbroiled meats) within 7 days (or 5 half-lives) before the first dose of study drug or throughout the study.
  9. The subject has consumed caffeine or xanthine-containing products within 48 hours (or 5 half-lives) before the first dose of study drug or throughout the study.
  10. The subject is a smoker or has used nicotine or nicotine-containing products (eg, snuff, nicotine patch, nicotine chewing gum, mock cigarettes, or inhalers) within 6 months before the first dose of study drug.
  11. The subject has a history of alcohol abuse or drug addiction within the last year, excessive alcohol consumption (regular alcohol intake >21 units per week for male subjects and >14 units of alcohol per week for female subjects; 1 unit is equal to approximately 1/2 pint [200 mL] of beer, 1 small glass [100 mL] of wine, or 1 measure.
  12. The subject has a positive test result for drugs of abuse, alcohol, or cotinine (indicating active current smoking) at Screening or Check-in.
  13. The subject is involved in strenuous activity or contact sports within 24 hours before the first dose of study drug or throughout the study.
  14. The subject has donated blood or blood products >450 mL within 30 days before the first dose of study drug.
  15. The subject has a history of relevant drug and/or food allergies (ie, allergy to midazolam, vonoprazan, or their [including cherries] or any significant food allergy that could preclude a standard diet in the clinical unit).
  16. The subject has received study drug in another study within 30 days of dosing.
  17. Female subject is pregnant or lactating, intends to become pregnant before, during, or within 4 weeks after participating in this study, or intends to donate ova during this time period.
  18. The subject has a history of acute narrow-angle glaucoma.
  19. In the opinion of the investigator, the subject is not suitable for entry into the study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Midazolam single doses / Vonoprazan multiple doses

    Single oral doses of 2 mg of midazolam syrup on Day 1 and Day 9 and twice daily (BID) doses of 20 mg vonoprazan oral tablets on Days 2 through 10

    Drug: Vonoprazan · Drug: Midazolam

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Midazolam

    AUC0-t was measured for midazolam alone on Day 1 and for midazolam administered with vonoprazan on Day 9.

    Time frame: Day 1 (midazolam alone): Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours post-dose; Day 9 (midazolam and vonoprazan): Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours post-dose

  2. Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Midazolam

    AUC0-inf was measured for midazolam alone on Day 1 and for midazolam administered with vonoprazan on Day 9.

    Time frame: Day 1 (midazolam alone): Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours post-dose; Day 9 (midazolam and vonoprazan): Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours post-dose

  3. Maximum Observed Plasma Concentration (Cmax) of Midazolam

    Cmax was measured for midazolam alone on Day 1 and for midazolam administered with vonoprazan on Day 9.

    Time frame: Day 1 (midazolam alone): Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours post-dose; Day 9 (midazolam and vonoprazan): Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours post-dose

07

Results

Posted Mar 17, 2023

Participant flow

20 participants were enrolled at a single study center in the United States.

Participant flow — Overall Study
MilestoneAll Participants
Started20
Completed20
Not completed0

Outcome measures

PrimaryArea Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Midazolam

AUC0-t was measured for midazolam alone on Day 1 and for midazolam administered with vonoprazan on Day 9.

Time frame:
Day 1 (midazolam alone): Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours post-dose; Day 9 (midazolam and vonoprazan): Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours post-dose
Reported as:
Mean · Nanogram Hours per Milliliter (ng•h/mL)
Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Midazolam
Nanogram Hours per Milliliter (ng•h/mL)Midazolam AloneMidazolam With Vonoprazan
Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Midazolam24.2 ± 8.7650.7 ± 39.8
Statistical analysis
  • Midazolam Alone vs Midazolam With Vonoprazan · Geometric least squares mean ratio: 192.4 · 90% CI 152.8 to 242.4
PrimaryArea Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Midazolam

AUC0-inf was measured for midazolam alone on Day 1 and for midazolam administered with vonoprazan on Day 9.

Time frame:
Day 1 (midazolam alone): Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours post-dose; Day 9 (midazolam and vonoprazan): Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours post-dose
Reported as:
Mean · Nanogram Hours per Milliliter (ng•h/mL)
Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Midazolam
Nanogram Hours per Milliliter (ng•h/mL)Midazolam AloneMidazolam With Vonoprazan
Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Midazolam25.5 ± 9.0052.3 ± 39.8
Statistical analysis
  • Midazolam Alone vs Midazolam With Vonoprazan · Geometric least squares mean ratio: 188.9 · 90% CI 150.6 to 236.9
PrimaryMaximum Observed Plasma Concentration (Cmax) of Midazolam

Cmax was measured for midazolam alone on Day 1 and for midazolam administered with vonoprazan on Day 9.

Time frame:
Day 1 (midazolam alone): Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours post-dose; Day 9 (midazolam and vonoprazan): Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours post-dose
Reported as:
Mean · Nanograms per Milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of Midazolam
Nanograms per Milliliter (ng/mL)Midazolam AloneMidazolam With Vonoprazan
Maximum Observed Plasma Concentration (Cmax) of Midazolam10.3 ± 3.6120.3 ± 9.55
Statistical analysis
  • Midazolam Alone vs Midazolam With Vonoprazan · Geometric least squares mean ratio: 193.4 · 90% CI 160.5 to 233.1

Adverse events

Collected over Day 1 to Day 25. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Midazolam Alone0/20 (0%)0/20 (0%)0/20 (0%)
Vonoprazan Alone0/20 (0%)0/20 (0%)4/20 (20%)
Midazolam With Vonoprazan0/20 (0%)0/20 (0%)2/20 (10%)
Most frequent other events
Most frequent other events
EventMidazolam AloneVonoprazan AloneMidazolam With Vonoprazan
NauseaGastrointestinal disorders0/202/200/20
DizzinessNervous system disorders0/201/200/20
HeadacheNervous system disorders0/200/201/20
SomnolenceNervous system disorders0/200/201/20
Gastrooesophageal reflux diseaseGastrointestinal disorders0/201/200/20
Feeling drunkGeneral disorders0/200/201/20
RhinorrhoeaRespiratory, thoracic and mediastinal disorders0/201/200/20
Dermatitis contactSkin and subcutaneous tissue disorders0/201/200/20

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Participants
Mean32.3 ± 7.17
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female8
Male12
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants
Hispanic or Latino8
Not Hispanic or Latino12
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander1
Black or African American7
White10
More than one race1
Unknown or Not Reported0
08

Study locations

1 site
  • PPD Development, LP
    Austin, Texas 78744, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Nov 2020, 1 month.

Results were first posted in Mar 2023, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2020
First posted
Sep 11, 2020
StartActual
Sep 15, 2020
Primary completionActual
Nov 13, 2020
CompletionActual
Nov 25, 2020
Results first posted
Mar 17, 2023
Last update
Mar 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04545944
Lead sponsor
Phathom Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Sep 11, 2020
Start date
Sep 15, 2020
Primary completion
Nov 13, 2020
Completion
Nov 25, 2020
Results posted
Mar 17, 2023
Last update
Mar 17, 2023

Study contacts

Medical Director
study director · Phathom Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vonoprazan · Midazolam

Start the discussion